Bayer and Puhe BioPharma sign global license for PRMT5 inhibitor in Phase I trials

Bayer has announced a significant advancement in its precision oncology pipeline by entering into an exclusive global licensing agreement with Suzhou Puhe BioPharma Co., Ltd. This collaboration focuses on the development of an innovative oral PRMT5 inhibitor, specifically designed to target MTAP-deleted tumors. Through this agreement, Bayer gains worldwide rights to develop, produce, and commercialize the MTA-cooperative PRMT5 inhibitor, known under the development name BAY 3713372.

The focus of this strategic partnership is the exploration of BAY 3713372's potential to improve treatment outcomes for patients affected by MTAP-deleted tumors, which are known to have a challenging prognosis. The Phase I clinical trial, already underway, marks an important step in assessing the safety, tolerability, and preliminary efficacy of this investigational treatment in human subjects.

Dr. Juergen Eckhardt, who leads Business Development and Licensing at Bayer’s Pharmaceuticals Division, expressed optimism regarding the PRMT5 inhibitor’s innovative mechanism. He emphasized its ability to selectively target cancer cells while preserving healthy ones, thereby holding promise for significant advancements in cancer treatment. This initiative aligns with Bayer’s goal to establish a transformative and distinctive oncology pipeline focusing on precision medicine.

Yongqi Guo, CEO of Puhe BioPharma, underscored the potential of the MTA-cooperative PRMT5 inhibitors in addressing MTAP-deleted tumors, which make up a substantial percentage of all cancers. These deletions exacerbate cancer cell vulnerability by increasing levels of MTA, which BAY 3713372 specifically targets by binding to the PRMT5-MTA complex. This targeted approach exploits the cancer cells' unique weaknesses, offering a promising therapeutic avenue. The compound has shown brain penetration capabilities in preclinical studies, broadening its potential application to include brain tumors and CNS metastases.

MTAP deletions are implicated in 10 to 30 percent of various cancers and are associated with aggressive types such as pancreatic cancer and glioblastoma, which often have limited treatment options. Dr. Dominik Ruettinger from Bayer’s Pharmaceuticals Division highlighted the promising trajectory of this research program, driven by a commitment to providing innovative treatments for cancer patients with significant unmet medical needs.

The ongoing Phase I trial aims to collect essential data on BAY 3713372, including its pharmacokinetics and pharmacodynamics, to evaluate its effectiveness as a targeted therapy against MTAP-deleted tumors. The collaboration between Bayer and Puhe BioPharma symbolizes a concerted effort to advance this promising therapy from the lab to clinical settings, potentially offering a new hope for patients worldwide.

Bayer continues to cement its position as a leader in the life sciences industry, leveraging its extensive expertise and resources to develop groundbreaking treatments. The company is dedicated to pushing the boundaries of medical science to address complex health challenges, reflecting its broader commitment to fostering global health and wellbeing.